|
《循证医学》杂志与中国胸部肿瘤研究协作组（CTONG）合作，专注于胸部肿瘤的基础、流行病学、诊断、医疗决策、治疗和康复等的医学专业期刊。
以提高胸部肿瘤患者健康为主要目标，发表高质量知识和信息，引导和启发医务人员和其他研究者为患者提供最优临床决策。力争成为最具影响力和广泛阅读的胸部肿瘤专科期刊。
价值观：科学、前瞻、创新。
《循证医学》杂志正致力于发展成中英文版的双语期刊，影响世界上使用人数最多的两种语言的读者。
发表哪些类型的文章？ 《循证医学》杂志发表原创性论著、综述和教育文章、新闻、以及评论等。 发表的类型包括临床研究方案、各期临床试验、meta分析等几乎所有研究类型。欢迎阴性结果的研究。
投稿 欢迎来自全世界的医生与其他群体投稿。
出版方式 《循证医学》杂志是一本在线优先出版的刊物，官方网站为 jebm.cn。所有内容会首先在网站上刊出。所有的文章均可在线免费阅读。 从2024年1月起，《循证医学》杂志采用连续出版的模式，网站每周甚至每天会不定时更新。 文章一经接收一律刊出全文，公众免费阅读，且没有字数限制。
编辑团队 《循证医学》杂志工作团队主要来自中国各地中国胸部肿瘤研究协作组（CTONG）主要成员单位，编辑根据自身专长加入不同专业和亚专业编辑团队。电子邮件是联系编辑团队的最佳方式。
《循证医学》于2001年创刊，是经国家新闻出版署批准，广东省卫生健康委员会主管，由广东省循证医学科研中心、广东省人民医院和中山大学附属第三医院主办的医学学术期刊。ISSN 1671-5144，CN 44-1548/R，为双月刊、每期64页。 Journal of Evidence-based Medicine was founded in 2001,approved by the National Press and Publication Administration, in charge of theHealth Commission of Guangdong Province, and sponsored by the Guangdong ScientificResearch Center of Evidence-based Medicine, Guangdong Provincial People'sHospital and the Third Affiliated Hospital of Sun Yat-sen University. ISSN1671-5144, CN 44-1548/R, publishes bi-monthly, and 64 pages per issue.
《循证医学》杂志现已被CNKI中国期刊全文数据库、万方数据——数字化期刊群、重庆维普—中文科技期刊数据库、中国生物医学文献数据库等国内多家数据库全文收录，2004年3月被中国科学技术信息研究所评定为“中国科技论文统计源期刊（中国科技核心期刊）”；2005年5月荣获首届《CAJ-CD规范》执行优秀期刊奖。2006年加入中国抗癌协会系列杂志。 Journal of Evidence-based Medicine has been fullyincluded in CNKI, Wanfang data, VIP, SinoMed and other domestic databases. InMarch 2004, it was assessed as "Source Journals for Chinese Scientific andTechnical Papers and Citations" by Institute of Scientific and TechnicalInformation of China. In May 2005, it won the first "CAJ-CD Standard"Execution Outstanding Issue Award. In 2006, it joined in the ChineseAnti-Cancer Association series journals. 荣誉主编吴一龙教授，肿瘤学教授、国际肺癌研究会（IASLC）杰出科学奖获得者，广东省人民医院首席专家，广东省肺癌研究所名誉所长，中国胸部肿瘤协作组（C-TONG）主席。
Honorary Editor in Chief WU Yi-long, Professor of Oncology, winner of IASLCOutstanding Science Award, Chief Expert of Guangdong Provincial People'sHospital, Honorary Director of Guangdong Lung Cancer Institute, President ofChinese Thoracic Oncology Group(C-TONG).
主编张绪超教授，研究员、广东省肺癌研究所所长、医学研究部主任，2018广东省杰出青年医学人才。中国临床肿瘤学会（CSCO）理事会常务理事、CSCO肿瘤生物标志物专家委员会秘书、广东省转化医学会肿瘤学分会主任委员。 Editor in Chief ZHANG Xu-chao，Professor, Researcher, Director of Guangdong Lung CancerInstitute, Director of Medical Research Department, and winner of 2018 OutstandingYoung Medical Talents in Guangdong Province. Executive Director of the Councilof Chinese Society of Clinical Oncology(CSCO), Secretary of CSCO TumorBiomarkers Expert Committee, Chairman of Cancer Branch of Guangdong TranslationalMedical Association.
本刊以广大医药卫生技术人员和医疗、教学、科研管理工作者为读者对象，立足临床医学，介绍循证医学的理念、方法及相关知识，探讨符合中国国情的循证医学实践，促进国内外医学学术交流和医学科学发展。 Based on clinical medicine, our journal introduces theconcept, methods and related knowledge of evidence-based medicine, discussesthe practice of evidence-based medicine in line with China's nationalconditions, and promotes the medical academic exchanges and medical sciencedevelopment at home and abroad, with the majority of medical and healthtechnical personnel as the target readers.
本刊以临床实践指导性和转化医学研究为特色，设置的主要栏目有：述评、临床肿瘤研究进展、循证评价、论著（主要覆盖肿瘤学临床研究、基础研究和转化应用研究等）、循证医学理论与方法研究、综述与讲座、临床指引与共识、教育与争鸣、循证病例讨论等。 Featuring clinical practice guidance and translationalmedicine research, this journal has set up the following main columns:comment,advances in clinical oncology research, evidence-based reviews, originalarticles (mainly covering clinical oncology research, basic research,translational applied research, etc.), research on theories and methods ofevidence-based medicine, reviews and lectures, clinical guidelines andconsensus, education and contention, and evidence-based clinical casediscussion, etc.
本刊感兴趣的研究领域包括：实验肿瘤学、肿瘤临床研究、细胞和肿瘤生物学，肿瘤血管生成，动物模型，肿瘤转移，癌症抗原及免疫应答，细胞信号和分子生物学，流行病学，癌症和分子靶标的遗传和分子谱分析，癌症干细胞，DNA损伤和修复，细胞周期，凋亡，分子病毒学以及基于疫苗和抗体的肿瘤治疗，靶向治疗与免疫治疗等相关预测预后标志物，耐药性机制，药物遗传学和药物基因组学，人类肿瘤的大规模分子表征，诊断性生物标志物，具有潜在临床应用潜力的创新影像学和其他新方法，临床遗传学和微小肿瘤检测。 Our research areas of interests include(but are notlimited to): Experimental oncology, tumor clinical research, cell and tumorbiology, tumor angiogenesis, animal models, tumor metastasis, cancer antigensand immune responses, cell signaling and molecular biology, epidemiology,genetic and molecular profiling of cancer and molecular targets, cancer stemcells, DNA damage and repair, cell cycle, apoptosis, molecular virology, andvaccine-and antibody-based tumor therapy, targeted therapy and immunotherapy, resistancemechanisms, pharmacogenetics and pharmacogenomics, large-scale molecularcharacterization of human tumors, diagnostic biomarkers, innovative imaging andother novel methods with potential for clinical application, clinical geneticsand detection of minimal tumors.
Starting from February 1, 2011, Evidence-based Medicineadopted the ScholarOne Manuscripts online submission system of Thomson ReutersGroup at the submission website: http://mc03.manuscriptcentral.com/jebm, or login to our website: http://www.jebm.cn/, and follow the website prompts.Sincerely welcome to contribute. 欢迎新老朋友订阅本刊，本刊通过全国各地邮政局发行，邮发代号 46-326。国内定价每期25元，全年定价150元。欲订阅者请从全国各地邮局订购，也可直接从本刊编辑部订购。 Welcome to subscribe our journal, we passes countrywidepost office to issue, mail sends code 46-326. Domestic pricing 25 yuan perissue, the annual pricing of 150 yuan. For subscribers, please order from postoffices all over the country or directly from our editorial office.
地址：广东省广州市越秀区惠福西路123号广东省人民医院惠福分院《循证医学》编辑部（510180） Address: Editorial Office of Evidence-based Medicine,Guangdong Provincial People's Hospital, No.123, Huifuxi Road, Guangzhou 510180,China | 
